Skip to main content
. 2018 Jun 18;13(6):e0198812. doi: 10.1371/journal.pone.0198812

Fig 3. Overall survival in patients treated with sorafenib; patients with 0–2 prognostic factors versus patients with 3–4 prognostic factors.

Fig 3